VIRIDIAN THERAPEUTICS INC's ticker is VRDN and the CUSIP is 92790C104. A total of 106 filers reported holding VIRIDIAN THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.26 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,107,000 | -39.8% | 1,050,000 | -6.7% | 2.15% | -41.0% |
| Q2 2023 | $26,763,750 | +10.7% | 1,125,000 | +18.4% | 3.64% | +5.2% |
| Q1 2023 | $24,168,000 | -17.3% | 950,000 | -5.0% | 3.46% | +1.1% |
| Q4 2022 | $29,210,000 | +42.4% | 1,000,000 | 0.0% | 3.42% | +35.7% |
| Q3 2022 | $20,510,000 | -16.9% | 1,000,000 | -33.3% | 2.52% | +41.7% |
| Q3 2021 | $24,675,000 | +168.5% | 1,500,000 | +172.7% | 1.78% | +98.3% |
| Q1 2021 | $9,191,000 | – | 550,000 | – | 0.90% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 2,699,865 | $78,863,057 | 13.28% |
| COMMODORE CAPITAL LP | 2,020,166 | $59,009 | 8.89% |
| ACUTA CAPITAL PARTNERS, LLC | 396,500 | $11,581,765 | 7.13% |
| Fairmount Funds Management LLC | 1,369,623 | $40,006,688 | 6.35% |
| Paradigm Biocapital Advisors LP | 1,751,167 | $51,151,588 | 6.00% |
| Vivo Capital, LLC | 1,678,207 | $49,020 | 5.64% |
| TCG Crossover Management, LLC | 983,610 | $28,731,248 | 5.07% |
| Kynam Capital Management, LP | 1,034,697 | $30,223,499 | 4.64% |
| Octagon Capital Advisors LP | 824,200 | $24,074,882 | 3.75% |
| Logos Global Management LP | 1,000,000 | $29,210,000 | 3.42% |